GlobeNewswire

Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
05/11/2026
- Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing [...]
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
05/11/2026
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Sparrow Pharmaceuticals Announces Expansion Cohorts in Phase 2b CAPTAIN-T2D Trial to Evaluate Clofutriben Across the Full Range of Cortisol Levels in Difficult-to-Control Type 2 Diabetes
05/11/2026
CAPTAIN-T2D remains on track, with topline data from the original and expansion cohorts expected by end-of-year (EOY) 2027 to enable pivotal Phase 3 readiness BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sparrow [...]
REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026
05/11/2026
Board of Directors Recommends a Vote FOR Each Proposal, Including a Reverse Stock Split Authorization Intended to Provide Flexibility to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Stockholders [...]
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
05/11/2026
Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose MIRAMAR, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics [...]
John Patrick University and Advanced Imaging Review Launch “Grow Your Own” Program to Build Healthcare Imaging Talent
05/11/2026
New initiative addresses radiology shortage and helps hospitals and health systems develop existing employees into radiologic technologists and advanced imaging professionals while they continue working SOUTH BEND, Ind [...]
Octo Health Launches Beta to Make Proactive, Personalized Healthcare More Accessible
05/11/2026
Octo Health brings medical records, lab results, medications and health data into one health timeline, giving consumers a more complete picture of their health By combining annual testing of more than 100 biomarkers [...]
Precision Optics Announces $2 Million Follow-On Order from Existing Top-Tier Aerospace Customer
05/11/2026
Order received ahead of expectations driving further conviction in forecasted fiscal 2027 results LITTLETON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a [...]
INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable
05/11/2026
Flexible financing options help patients manage treatment costs as INVO continues to expand its fertility services SARASOTA, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “ [...]
Koç Healthcare Marks European Fertility Week 2026 with a Call for More Supportive Workplaces
05/11/2026
Under this year’s “Double Duty” theme, two doctors highlight the often unseen demands of fertility treatment alongside professional and family responsibilities ISTANBUL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Koç Healthcare [...]
Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist
05/11/2026
CMS establishes $314.54 reimbursement rate for CPT code 97610 for 2027, an approximately 21% reduction vs 2026 rate of $397.81 2027 Hospital outpatient rate for 97610 code set at $235.04, an approximately 15% increase [...]
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
05/11/2026
New investor presentation outlines scientific rationale for combining Ampligen’s immune-stimulating activity with daraxonrasib’s targeted RAS inhibition to potentially prolong clinical benefit Previously reported [...]
Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry
05/11/2026
The 6-month target lesion primary patency (TLPP) 1 and access circuit primary patency (ACPP) 2 for patients in the arteriovenous fistula (AVF) cohort were 92.7% and 76.7%, respectively The real-world patency results [...]
Regen BioPharma, Inc. Provides Shareholder Update on Company’s Activities and Direction
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) Update on Regen’s recent activities (i.e.: debt payoff, financing, potential joint ventures): The Company has recently paid off [...]
GenomOncology Integrates ARUP Laboratories’ Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive Agreement
05/11/2026
Gene-level phenotype-matching scores from patient Human Phenotype Ontology (HPO) terms now feed directly into variant prioritization for rare disease exome, genome, and large-panel germline testing, alongside new [...]
Rectify Pharmaceuticals Presents Translational Data on RTY-406 at AASLD 2026 Liver Meeting
05/11/2026
Presentation highlights preclinical characterization of RTY-406, an oral, once-daily investigational therapy targeting underlying drivers of hepatobiliary diseases BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rectify [...]
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
05/11/2026
In real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after [...]
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
05/11/2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD) Presentation to take place on Monday, [...]
Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
05/11/2026
Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control RTX001 was well tolerated with no infusion-related serious adverse reactions; [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum